Abstract: This disclosure relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to PD-1 and block the interaction between PD-1 and PD-L1/PD-L2. The disclosure also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies, portions of fusion proteins or bispecific antibodies. Nucleic acid molecules encoding the antibodies, hybridomas, and methods for expressing antibodies are also provided. Pharmaceutical compositions comprising the antibodies are also provided. This disclosure also provides use of these antibodies to enhance T-cell function and upregulate cell-mediated immune responses for the treatment and prevention of various diseases.

Abstract: The present disclosure is directed towards genetically engineered TCR-T cells to recognize tumor antigens and simultaneously secrete a binding protein that blocks an immune checkpoint molecule and TGF?. These engineered T cells demonstrate stronger antitumor response and reduced T cell exhaustion. The present disclosure provides immunotherapy against HPV- or EBV-positive cancers, among others.

Abstract: Photopolymerizable topcoat and color coat gel compositions suitable for forming a photopolymerized nail coating are described. Both gel compositions include a mixture of one or more pre-formed polymers, a (meth)acrylic monomer, a multi-(meth)acrylate crosslinker, a UV photoinitiator and an antioxidant. The color coat gel composition includes pigments, a smectite clay and silica.

Abstract: Provided are T cell receptors that recognize or bind to Epstein-Barr virus (EBV) antigens, genetically engineered cells, and cell-based therapies.

Abstract: T cell receptors that recognize or bind to human papilloma virus (HPV) antigens, genetically engineered cells and cell-based therapies are provided.

Abstract: This disclosure relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to PD-1 and block the interaction between PD-1 and PD-L1/PD-L2. The disclosure also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies, portions of fusion proteins or bispecific antibodies. Nucleic acid molecules encoding the antibodies, hybridomas, and methods for expressing antibodies are also provided. Pharmaceutical compositions comprising the antibodies are also provided. This disclosure also provides use of these antibodies to enhance T-cell function and upregulate cell-mediated immune responses for the treatment and prevention of various diseases.

Abstract: The present disclosure is directed towards genetically engineered TCR-T cells to recognize tumor antigens and simultaneously secrete a binding protein that blocks an immune checkpoint molecule and TGF-beta. These engineered T cells demonstrate stronger antitumor response and reduced T cell exhaustion. The present disclosure provides immunotherapy against HPV- or EBV-positive cancers, among others.

Abstract: The invention is directed to a masked chimeric antigen receptor, comprising: (a) a masking peptide; (b) one or more antigen-specific targeting domains; (c) an extracellular spacer domain; (d) a transmembrane domain; (e) at least one co-stimulatory domain; and (f) an intracellular signaling domain. The mCARs are activated upon cleavage of the masking peptide.

Abstract: The invention is directed to a masked chimeric antigen receptor, comprising: (a) a masking peptide; (b) one or more antigen-specific targeting domains; (c) an extracellular spacer domain; (d) a transmembrane domain; (e) at least one co-stimulatory domain; and (f) an intracellular signaling domain. The mCARs are activated upon cleavage of the masking peptide.